drugset / Trial / NCT01513200

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

NCT01513200

Phase 1 Completed 12 enrolled Stealth BioTherapeutics Inc.
RandomizedCrossoverQuadruple-blindBasic science

Summary

This will be a phase 1 randomized, double-blind crossover trial enrolling approximately 12 healthy volunteers to assess whether intravenous (IV) UFH and IV Bendavia administered together have any significant impact on the pharmacodynamic effects of UFH and the pharmacokinetics of Bendavia.

Timeline

Start
2012-01
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Elamipretide Peptide 0.25 mg/kg Intravenous
Subject Heparin Other / unclassified 12 iu/kg Intravenous

Indications

No indication recorded.